Faron

Faron, a clinical stage biopharmaceutical company with the slogan "A CLEVER Approach to Fight Cancer," is focused on developing novel immunotherapies to address unmet medical needs. Headquartered in Turku, Finland, and Boston, Massachusetts, its flagship program is bexmarilimab, an investigational precision immunotherapy. Currently in Phase I/II development, bexmarilimab is a notable anti-Clever-1 antibody designed to convert immune suppression into immune activation, specifically targeting hematological malignancies.

Founded in 2007, Faron operates within the Biopharma, Biotechnology, and Pharmaceutical industries. The company is publicly traded on AIM under the ticker 'FARN' as well as on Nasdaq First North Growth Market under the ticker FARON. Its most recent financial activity includes a €3.20M Post-IPO Debt investment in March 2024 from IPF Partners, indicating continuous investor confidence in its innovative therapeutic approaches.